Home » Stocks » HOOK

HOOKIPA Pharma Inc. (HOOK)

Stock Price: $15.20 USD 0.66 (4.54%)
Updated May 6, 2021 4:00 PM EDT - Market closed
After-hours: $15.25 +0.05 (0.33%) May 6, 5:30 PM
Market Cap 433.50M
Revenue (ttm) 19.58M
Net Income (ttm) -44.08M
Shares Out 25.99M
EPS (ttm) -1.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 6
Last Price $15.20
Previous Close $14.54
Change ($) 0.66
Change (%) 4.54%
Day's Open 14.45
Day's Range 13.48 - 15.20
Day's Volume 306,270
52-Week Range 8.10 - 15.52

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

HOOKIPA Pharma Inc. (HOOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 day ago - Zacks Investment Research

NEW YORK and VIENNA, Austria, April 29, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...

1 week ago - GlobeNewsWire

NEW YORK and VIENNA, Austria, April 14, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...

3 weeks ago - GlobeNewsWire

NEW YORK and VIENNA, Austria, April 10, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...

3 weeks ago - GlobeNewsWire

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 17.86% and 0.98%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Shares of HOOKIPA Pharma (NASDAQ:HOOK) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share decreased 15.00% over the past year to ($0.46), which beat the esti...

1 month ago - Benzinga

HOOKIPA Pharma Inc. (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

HOOKIPA Pharma (HOOK) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

3 months ago - Zacks Investment Research

Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics from its arenavirus immune-system reprogrammer platform. Hookipa has an infectious disease/oncology ...

4 months ago - Seeking Alpha

NEW YORK and VIENNA, Austria, Dec. 11, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, t...

4 months ago - GlobeNewsWire

NEW YORK and VIENNA, Austria, Dec. 08, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, t...

4 months ago - GlobeNewsWire

NEW YORK and VIENNA, Austria, Dec. 08, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, t...

4 months ago - GlobeNewsWire

HOOKIPA (HOOK) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

Gamida Cell (NASDAQ: GMDA) shares are trading higher on Monday following the company's Saturday GDA-201 presentation at the American Society of Hematology Annual Meeting. Gamida Cell is a biopharmaceuti...

Other stocks mentioned: GMDA
4 months ago - Benzinga

NEW YORK and VIENNA, Austria, Dec. 07, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus ...

4 months ago - GlobeNewsWire

NEW YORK and VIENNA, Austria, Nov. 30, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus ...

5 months ago - GlobeNewsWire

Shares of HOOKIPA Pharma (NASDAQ:HOOK) were unchanged after the company reported Q3 results. Quarterly Results Earnings per share were down 17.78% year over year to ($0.53), which missed the estimate of...

5 months ago - Benzinga

NEW YORK and VIENNA, Austria, Nov. 12, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus ...

5 months ago - GlobeNewsWire

NEW YORK and VIENNA, Austria, Nov. 03, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus ...

6 months ago - GlobeNewsWire

Peer reviewed article in OncoImmunology demonstrates promising preclinical results for the novel cancer therapy targeting Human Papillomavirus 16 (HPV16) E6/E7 

7 months ago - GlobeNewsWire

NEW YORK and VIENNA, Austria, Sept. 16, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and...

7 months ago - GlobeNewsWire

NEW YORK and VIENNA, Austria, Sept. 09, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and...

7 months ago - GlobeNewsWire

HOOKIPA Pharma Inc. (HOOK) delivered earnings and revenue surprises of 39.13% and 138.32%, respectively, for the quarter ended June 2020.

8 months ago - Zacks Investment Research

NEW YORK and VIENNA, Austria, Aug. 13, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and ...

8 months ago - GlobeNewsWire

HOOKIPA Pharma Inc. (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

9 months ago - Zacks Investment Research

NEW YORK and VIENNA, Austria, Aug. 04, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and ...

9 months ago - GlobeNewsWire

HOOKIPA Pharma Inc. (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

9 months ago - Zacks Investment Research

NEW YORK and VIENNA, Austria, Aug. 03, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and ...

9 months ago - GlobeNewsWire

NEW YORK and VIENNA, Austria, June 22, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and ...

10 months ago - GlobeNewsWire

NEW YORK and VIENNA, Austria, June 19, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and ...

10 months ago - GlobeNewsWire

NEW YORK and VIENNA, Austria, June 17, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers bas...

10 months ago - GlobeNewsWire

HOOKIPA (HOOK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

10 months ago - Zacks Investment Research

HOOKIPA Pharma Inc (HOOK) delivered earnings and revenue surprises of -10.26% and -15.13%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

NEW YORK and VIENNA, Austria, May 14, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and c...

11 months ago - GlobeNewsWire

HOOKIPA Pharma Inc (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

11 months ago - Zacks Investment Research

HOOKIPA Pharma Inc. (HOOK) CEO Joern Aldag on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

HOOKIPA Pharma and Viking Therapeutics could catch first at some point this year. Here's why.

Other stocks mentioned: VKTX
1 year ago - The Motley Fool

NEW YORK and VIENNA, Austria, Jan. 06, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and ...

1 year ago - GlobeNewsWire

NEW YORK and VIENNA, Austria, Dec. 30, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and ...

1 year ago - GlobeNewsWire

Hookipa's Technology Appears To Be A Vaccine Gamechanger Against Infectious Disease And Cancer

1 year ago - Seeking Alpha

Christine D. Baker has joined as Chief Business Officer  Roman Necina, PhD, will join as Chief Technology Officer 

1 year ago - GlobeNewsWire

NEW YORK and VIENNA, Austria, Sept. 19, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and...

1 year ago - GlobeNewsWire

NEW YORK and VIENNA, Austria, Aug. 29, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and ...

1 year ago - GlobeNewsWire

Hookipa stated that the FDA allowed the clearance of an IND needed to begin a phase 1/2 study to treat HPV-positive cancers using HB-201.

1 year ago - Seeking Alpha

Hookipa Pharma Inc. (NASDAQ: HOOK) is not a household name, or even well-known within the biotech industry, but it is making waves on Friday after the firm announced an update from the U.S.

1 year ago - 24/7 Wall Street

Hookipa Pharma Inc. shares jumped 40% in late trading Thursday after the company announced that the Food and Drug Administration approved a study of the company's immunotherapy approach to certain cancers.

1 year ago - Market Watch

About HOOK

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cance... [Read more...]

Industry
Biotechnology
IPO Date
Apr 18, 2019
Stock Exchange
NASDAQ
Ticker Symbol
HOOK
Full Company Profile

Financial Performance

In 2020, HOOKIPA Pharma's revenue was $19.58 million, an increase of 63.99% compared to the previous year's $11.94 million. Losses were -$44.08 million, 2.43% more than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for HOOKIPA Pharma stock is "Buy." The 12-month stock price forecast is 22.00, which is an increase of 44.74% from the latest price.

Price Target
$22.00
(44.74% upside)
Analyst Consensus: Buy